Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 15/20 | 0.68 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4422678 | 0.87 | CASP3 (0.78) | CASP3CA2CA9 | |
| SCHEMBL4552210 | 0.81 | CASP3 (1.00) | CASP3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4552076 | 0.81 | CASP3 (1.00) | CASP3CA2CA9NPC1RAB9A | |
| SCHEMBL14028006 | 0.80 | CASP3 (0.60) | CASP3CA2CA9NPC1RAB9A | |
| SCHEMBL4551164 | 0.80 | CASP3 (0.76) | CASP3NPC1RAB9ASMN1; SMN2NPSR1 | |
| SCHEMBL4552118 | 0.79 | CASP3 (0.78) | CASP3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4551146 | 0.79 | CASP3 (0.78) | CASP3CA2CA9NPC1RAB9A | |
| SCHEMBL4416525 | 0.79 | CASP3 (1.00) | CASP3CA2CA9NPC1RAB9A | |
| SCHEMBL4552413 | 0.78 | CASP3 (0.78) | CASP3CA2CA9NPC1RAB9A | |
| SCHEMBL4552243 | 0.78 | CASP3 (0.73) | CASP3NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1618205-A4 | METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS | CYTOVIA INC (US) | 2009-04-08 | — | — | EP | disclosed |
| US-7435750-B2 | Method of using substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| EP-1618205-A2 | METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS | Cytovia, Inc. (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050004005-A1 | Methods of treating diseases responsive to Induction of Apoptosis | CYTOVIA, INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004094648-A2 | METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS | CYTOVIA, INC. ET AL. (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004005-A1 | Methods of treating diseases responsive to Induction of Apoptosis | PDCD6IP, THUMPD1, CCAR2 | CASP3 90/4885CA2 4431/4885CA9 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.